Literature DB >> 35084601

Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis.

Guy Katz1, Alexis Ogdie2, Joshua F Baker3, Michael D George2.   

Abstract

INTRODUCTION: Depression, anxiety, and chronic pain are common comorbidities in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) and may substantially impact patient outcomes. We aimed to determine whether these comorbidities were associated with earlier TNF-inhibitor (TNFi) discontinuation.
METHODS: This retrospective cohort study using Optum's de-identified Clinformatics® Data Mart Database 2000-2014 identified patients with RA, PsA, and AS initiating a first TNFi. Depression/anxiety, chronic pain, and opioid use were identified using diagnosis codes and prescription fill data. Cox proportional hazards models were used to compare time to medication discontinuation in patients with or without each of these risk factors and to assess the additive effect of having multiple risk factors.
RESULTS: Among 33,744 patients initiating a TNFi (23,888 RA, 6443 PsA, 3413 AS), depression/anxiety, chronic pain, and opioid use were common, with ≥ 1 risk factor in 48.1%, 42.5%, and 55.4% of patients with RA, PsA, and AS respectively. Each risk factor individually was associated with a 5-7-month lower median treatment persistence in each disease (all p < 0.001). Presence of multiple risk factors had an additive effect on time to discontinuation with HR (95% CI) 1.19 (1.14-1.24), 1.41 (1.33-1.49), and 1.47 (1.43-1.73) for 1, 2, or 3 risk factors respectively in RA. Findings were similar in PsA and AS.
CONCLUSIONS: Depression, anxiety, chronic pain, and opioid use are common in inflammatory arthritis and associated with earlier TNFi discontinuation. Recognizing and managing these risk factors may improve treatment persistence, patient outcomes, and cost of care. Key Points • Depression, anxiety, chronic pain, and opioid use are common in patients with inflammatory arthritis. • In patients initiating treatment with a TNF-inhibitor, depression, anxiety, chronic pain, or recent opioid use are associated with sooner discontinuation of TNFi therapy. • Patients with multiple of these risk factors are even more likely to discontinue therapy sooner.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Depression; Pain; Rheumatoid arthritis; Spondyloarthritis; Treatment

Mesh:

Substances:

Year:  2022        PMID: 35084601      PMCID: PMC9058194          DOI: 10.1007/s10067-021-06045-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  31 in total

1.  Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis.

Authors:  Chris Dickens; Linda McGowan; David Clark-Carter; Francis Creed
Journal:  Psychosom Med       Date:  2002 Jan-Feb       Impact factor: 4.312

2.  Systematic review of depression and anxiety in psoriatic arthritis.

Authors:  Narainraj Kamalaraj; Carlos El-Haddad; Phillipa Hay; Kevin Pile
Journal:  Int J Rheum Dis       Date:  2019-04-26       Impact factor: 2.454

3.  [Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics].

Authors:  Mercedes Freire; Jesús Rodríguez; Ingrid Möller; Antonio Valcárcel; Carmelo Tornero; Gemma Díaz; Yolanda Armendáriz; Silvia Paredes
Journal:  Reumatol Clin       Date:  2010-06-15

Review 4.  Pain in systemic inflammatory rheumatic diseases.

Authors:  Fabiola Atzeni; Ignazio Francesco Masala; Fausto Salaffi; Manuela Di Franco; Roberto Casale; Piercarlo Sarzi-Puttini
Journal:  Best Pract Res Clin Rheumatol       Date:  2015-05-19       Impact factor: 4.098

5.  Risk of Psychiatric Disorders following Ankylosing Spondylitis: A Nationwide Population-based Retrospective Cohort Study.

Authors:  Cheng-Che Shen; Li-Yu Hu; Albert C Yang; Benjamin Ing-Tiau Kuo; Yung-Yen Chiang; Shih-Jen Tsai
Journal:  J Rheumatol       Date:  2016-02-01       Impact factor: 4.666

6.  Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years.

Authors:  Maria L E Andersson; Björn Svensson; Stefan Bergman
Journal:  J Rheumatol       Date:  2013-11-01       Impact factor: 4.666

7.  Anxiety and depression in patients with rheumatoid arthritis.

Authors:  Ahmet Isik; Suleyman Serdar Koca; Abdullah Ozturk; Osman Mermi
Journal:  Clin Rheumatol       Date:  2006-08-29       Impact factor: 3.650

8.  Impact of ankylosing spondylitis on depression: a nationwide cohort study.

Authors:  Jin-Sung Park; Hae-Dong Jang; Jae-Young Hong; Ye-Soo Park; Kyungdo Han; Seung-Woo Suh; Si-Yong Park; Bo-Taek Kim
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.379

9.  New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study.

Authors:  Matthias Englbrecht; Rieke Alten; Martin Aringer; Christoph G Baerwald; Harald Burkhardt; Nancy Eby; Jan-Paul Flacke; Gerhard Fliedner; Ulf Henkemeier; Michael W Hofmann; Stefan Kleinert; Christian Kneitz; Klaus Krüger; Christoph Pohl; Georg Schett; Marc Schmalzing; Anne-Kathrin Tausche; Hans-Peter Tony; Jörg Wendler
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

10.  The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis.

Authors:  Sizheng Zhao; Daniel Thong; Natasha Miller; Stephen J Duffield; David M Hughes; Laura Chadwick; Nicola J Goodson
Journal:  Arthritis Res Ther       Date:  2018-07-11       Impact factor: 5.156

View more
  1 in total

1.  Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.

Authors:  Maria Vassilaki; Cynthia S Crowson; John M Davis Iii; Stephanie Q Duong; David T Jones; Aivi Nguyen; Michelle M Mielke; Prashanthi Vemuri; Elena Myasoedova
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.